Open Public Consultation on the revision of the general pharmaceutical legislation

Fields marked with * are mandatory.

Introduction


The Pharmaceutical Strategy identifies flagship initiatives and other actions to ensure the delivery of tangible results. As part of the implementation of the strategy, the Commission is evaluating the general pharmaceutical legislation\(^1\) and assessing the impacts of possible changes in the legislation as described in the relevant inception impact assessment.

This public consultation aims to collect views of stakeholders and the general public in order to support the evaluation of the existing general pharmaceutical legislation and the impact assessment of its revision. It builds further on the public consultation\(^2\) conducted for the preparation of the pharmaceutical strategy for Europe. The replies to that consultation will be taken into account for the revision of the general pharmaceutical legislation. The present questionnaire should be seen as a continuation of that process.

In parallel, the legislation for medicines for rare diseases and children is being revised as well. Separate consultation activities have been carried out for that revision.

This questionnaire is available in all EU languages and you can reply in any EU language. You can pause any time and continue later. You can download your contribution once you have submitted your answers.

A summary on the outcome of the public consultation will be published by the Commission services on the ‘Have your say’ portal.

We thank you for your participation.


A report analysing the results of the pharmaceutical strategy consultation was published in November 2020.

About you
• Language of my contribution
  ○ Bulgarian
  ○ Croatian
  ○ Czech
  ○ Danish
  ○ Dutch
  ○ English
  ○ Estonian
  ○ Finnish
  ○ French
  ○ German
  ○ Greek
  ○ Hungarian
  ○ Irish
  ○ Italian
  ○ Latvian
  ○ Lithuanian
  ○ Maltese
  ○ Polish
  ○ Portuguese
  ○ Romanian
  ○ Slovak
  ○ Slovenian
  ○ Spanish
  ○ Swedish

• I am giving my contribution as
  ○ Academic/research institution
  ○ Business association
  ○ Company/business organisation
  ○ Consumer organisation
  ○ EU citizen
  ○ Environmental organisation
  ○ Non-EU citizen
* Which stakeholder group do you represent?
  - Individual member of the public
  - Patient or consumer organisation
  - Healthcare professional
  - Healthcare provider organisation (incl. hospitals, pharmacies)
  - Healthcare payer
  - Centralised health goods procurement body
  - Health technology assessment body
  - Academic researcher
  - Research funder
  - Learned society
  - European research infrastructure
  - Other scientific organisation
  - Environmental organisation
  - Pharmaceuticals industry
  - Chemicals industry
  - Pharmaceuticals traders/wholesalers
  - Medical devices industry
  - Public authority (e.g. national ministries of health, medicines agencies, pricing and reimbursement authorities)
  - EU regulatory partner / EU institution
  - Non-EU regulator / non-EU body
  - Other (Please specify)

If other, please specify:

[Text box: Cancer leagues]

* First name

[Text box: ECL]
Surname

Secretariat

Email (this won't be published)

ecl@europeancancerleagues.org

Organisation name

Association of European Cancer Leagues (ECL)

Organisation size

- Micro (1 to 9 employees)
- Small (10 to 49 employees)
- Medium (50 to 249 employees)
- Large (250 or more)

Transparency register number

Check if your organisation is on the transparency register. It's a voluntary database for organisations seeking to influence EU decision-making.

19265592757-25

Country of origin

Please add your country of origin, or that of your organisation.

- Afghanistan
- Åland Islands
- Albania
- Algeria
- American Samoa
- Andorra
- Angola
- Anguilla
- Djibouti
- Dominica
- Dominican Republic
- Ecuador
- Egypt
- El Salvador
- Equatorial Guinea
- Eritrea
- Libya
- Liechtenstein
- Lithuania
- Luxembourg
- Macau
- Madagascar
- Malawi
- Malaysia
- Saint Martin
- Saint Pierre and Miquelon
- Saint Vincent and the Grenadines
- Samoa
- San Marino
- São Tomé and Príncipe
- Saudi Arabia
- Senegal
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bonaire Saint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Estonia
Eswatini
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern and Antarctic Lands
Gabon
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar/Burma
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
<table>
<thead>
<tr>
<th>British Virgin Islands</th>
<th>Guyana</th>
<th>Niger</th>
<th>The Gambia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunei</td>
<td>Haiti</td>
<td>Nigeria</td>
<td>Timor-Leste</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Heard Island and McDonald Islands</td>
<td>Niue</td>
<td>Togo</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>Honduras</td>
<td>Norfolk Island</td>
<td>Tokelau</td>
</tr>
<tr>
<td>Burundi</td>
<td>Hong Kong</td>
<td>Northern Mariana Islands</td>
<td>Tonga</td>
</tr>
<tr>
<td>Cambodia</td>
<td>Hungary</td>
<td>North Korea</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>Cameroon</td>
<td>Iceland</td>
<td>North Macedonia</td>
<td>Tunisia</td>
</tr>
<tr>
<td>Canada</td>
<td>India</td>
<td>Norway</td>
<td>Turkey</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>Indonesia</td>
<td>Oman</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>Iran</td>
<td>Pakistan</td>
<td>Turks and Caicos Islands</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>Iraq</td>
<td>Palau</td>
<td>Tuvalu</td>
</tr>
<tr>
<td>Chad</td>
<td>Ireland</td>
<td>Palestine</td>
<td>Uganda</td>
</tr>
<tr>
<td>Chile</td>
<td>Isle of Man</td>
<td>Panama</td>
<td>Ukraine</td>
</tr>
<tr>
<td>China</td>
<td>Israel</td>
<td>Papua New Guinea</td>
<td>United Arab Emirates</td>
</tr>
<tr>
<td>Christmas Island</td>
<td>Italy</td>
<td>Paraguay</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Clipperton</td>
<td>Jamaica</td>
<td>Peru</td>
<td>United States</td>
</tr>
<tr>
<td>Cocos (Keeling) Islands</td>
<td>Japan</td>
<td>Philippines</td>
<td>United States Minor Outlying Islands</td>
</tr>
<tr>
<td>Colombia</td>
<td>Jersey</td>
<td>Pitcairn Islands</td>
<td>Uruguay</td>
</tr>
<tr>
<td>Comoros</td>
<td>Jordan</td>
<td>Poland</td>
<td>US Virgin Islands</td>
</tr>
<tr>
<td>Congo</td>
<td>Kazakhstan</td>
<td>Portugal</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>Cook Islands</td>
<td>Kenya</td>
<td>Puerto Rico</td>
<td>Vanuatu</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>Kiribati</td>
<td>Qatar</td>
<td>Vatican City</td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
<td>Kosovo</td>
<td>Réunion</td>
<td>Venezuela</td>
</tr>
<tr>
<td>Croatia</td>
<td>Kuwait</td>
<td>Romania</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Cuba</td>
<td>Kyrgyzstan</td>
<td>Russia</td>
<td>Wallis and Futuna</td>
</tr>
</tbody>
</table>
The Commission will publish all contributions to this public consultation. You can choose whether you would prefer to have your details published or to remain anonymous when your contribution is published. For the purpose of transparency, the type of respondent (for example, ‘business association’, ‘consumer association’, ‘EU citizen’) country of origin, organisation name and size, and its transparency register number, are always published. Your e-mail address will never be published. Opt in to select the privacy option that best suits you. Privacy options default based on the type of respondent selected.

**Contribution publication privacy settings**

The Commission will publish the responses to this public consultation. You can choose whether you would like your details to be made public or to remain anonymous.

- **Anonymous**
  Only organisation details are published: The type of respondent that you responded to this consultation as, the name of the organisation on whose behalf you reply as well as its transparency number, its size, its country of origin and your contribution will be published as received. Your name will not be published. Please do not include any personal data in the contribution itself if you want to remain anonymous.

- **Public**
  Organisation details and respondent details are published: The type of respondent that you responded to this consultation as, the name of the organisation on whose behalf you reply as well as its transparency number, its size, its country of origin and your contribution will be published. Your name will also be published.

- I agree with the [personal data protection provisions](#)

Looking back
As mentioned in the Inception Impact assessment, the revision aims to tackle the following problems:

- Unmet medical needs and market failures for medicines other than medicines for rare diseases and children;
- Unequal access to available and affordable medicines for patients across the EU;
- The current legislative framework may not be fully equipped to respond quickly to innovation;
- Inefficiency and administrative burden of regulatory procedures;
- Vulnerability of supply of medicines, shortages of medicines;
- Environmental challenges and sustainability;
- Any other issues, which might emerge from the evaluation.

Q1 In your opinion, are there any other issues that should be addressed in this revision?

800 character(s) maximum

1) The EMA should require the mandatory inclusion of patient-reported outcomes on their quality of life, and overall survival data. HTA bodies and patients should be involved in the design of clinical trials used for MA application, so that clinical trials' evidence is relevant for regulatory bodies and payers alike;
2) Establish a clear legal framework to maintain research collaborations, including data sharing respectful of the GDPR, between the EU and the EFTA countries and the UK;
3) Incentivise (eg delinkage) medicines developed in non-commercial/academic settings to tackle UMNs, increase competition, and reduce monopolies;
4) Establish legal adjustments for precision medicine in light of scientific advancements, and the use of ATMPs.

Q2 How has the legislation performed in terms of the following elements?

<table>
<thead>
<tr>
<th></th>
<th>Very well</th>
<th>Well</th>
<th>Moderately</th>
<th>Poorly</th>
<th>Very poorly</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Fulfilling its public health protection mission for patients and society.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Promoting the development of new medicines, especially for unmet medical needs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Enabling timely development of medicines at all times, including during crises.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Enabling timely authorisation, including scientific evaluation, of medicines in normal times.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Enabling timely authorisation, including scientific evaluation during crises.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>6. Adapting efficiently and effectively to technological and scientific advancements and innovation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Ensuring medicines are of high quality, safe and effective.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Addressing the competitive functioning of the market to support affordability.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Ensuring the availability of generic(^3) and biosimilar(^4) medicines.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(^3) &quot;Generic&quot; is a copy of a medicine based on simple or chemical molecules.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(^4) &quot;Biosimilar&quot; is a copy of a medicine based on biological molecules.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Ensuring that new medicines are timely available to patients in all EU countries.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Ensuring that medicines stay on the market at all times and that there are no shortages.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Ensuring that authorised medicines are manufactured, used and disposed of in an environmentally friendly manner.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Ensuring that the EU system for development, authorisation and monitoring of medicines, including its rules and procedures, is understandable and easy to navigate.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Attracting global investment for medicine innovation in the EU.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Is there any other aspect you would like to mention, including positive or unintended effects of the legislation, or would you like to justify your replies?

800 character(s) maximum
Pros:
- mechanisms to ensure safe medicines.
- A pharmacovigilance system that allows for quick reaction from the EU.

Cons:
- The EC should expand the Joint Procurement Agreement to jointly negotiate and purchase starting from, but not limited to, rare cancer health technologies.
- Art. 10 to be revised to increase competition and avoid monopolies where generics and biosimilars cannot enter the market.
- The fact that pharma companies can decide where and when to launch their products hampers equal access to medicines. The BlueBird case is a dangerous case study.
- Lack of systematic evaluation of the added value of new medicines.
- The increasing impact of pharmaceuticals on national healthcare budgets.
- Poor convergence among member states

Looking forward

This section reflects on possible solutions to address the problems identified in the inception impact assessment mentioned in the previous section.

Your contribution will help us in defining the way forward.

UNMET MEDICAL NEEDS

One of the aims of the strategy is to stimulate innovation and breakthrough therapies, especially in areas of ‘unmet medical need’.

Regulators, health technology assessment experts and representatives of bodies responsible for reimbursing or paying for medicines (‘payers’) are discussing a definition or a set of principles for ‘unmet medical needs’ in order to achieve the objectives of the general pharmaceutical legislation. The discussions reveal different perceptions of what is an ‘unmet medical need’. Convergence on this key concept should facilitate the design of clinical trials, generation of evidence and its assessment, and the quick availability on the market of these products and ensuring that innovation matches the needs of patients and of the national health systems.

The purpose of this question is to identify elements that are important in defining what is unmet medical need and in which areas of unmet medical need innovation should be stimulated.

[5] Please note that a similar discussion is taking place in the context of medicines for rare diseases and for children. The concept of ‘unmet needs’ in the context of rare diseases and children might be slightly differentiated compared to ‘unmet needs’ in the context of the general pharmaceutical legislation.

Q3 How important are the following elements for defining ‘unmet medical needs’?
<table>
<thead>
<tr>
<th>Criteria</th>
<th>Very important</th>
<th>Important</th>
<th>Fairly important</th>
<th>Slightly important</th>
<th>Not important</th>
<th>Don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Seriousness of a disease.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Absence of satisfactory treatment authorised in the EU.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. A new medicine has major therapeutic advantage over existing treatment(s).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Lack of access for patients across the EU to an authorised treatment.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Other (please specify).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined elements, or would you like to justify your replies?

800 character(s) maximum

- Criteria defining UMNs should be established in the EU legislation and detailed in scientific guidelines, which could be updated regularly. All the principles listed in the table are critical but open to interpretation. Measurable criteria defined with patients and academia should be foreseen to have an inclusive and transparent evaluation of “UMNs”.
- It is vital to develop and implement EU cancer registries that include the treatments employed, their effects, impact on quality of life, their clinical benefit and ultimately have a comprehensive data platform. This mechanism would encourage ameliorations and scientific developments.
- In terms of economic impact, high prices of medicines could be overcome with systematic joint procurement procedures as for the case of Spinraza.

INCENTIVES FOR INNOVATION

The general pharmaceutical legislation guarantees the pharmaceutical innovator, typically a company, regulatory data and market protection for its new medicinal product. This data protection makes sure that another pharmaceutical company cannot re-use the proprietary data of the innovator for 8 years. Market protection makes sure that a generic or biosimilar medicine cannot be marketed until 10 years after authorisation. This dual protection shields a pharmaceutical innovator from generics or biosimilars on the market for 10 years. This protection is part of the EU system of incentives for innovation. The EU regime of intellectual property protection provides an additional protection coverage but is beyond the scope of this questionnaire and the revision of the general pharmaceutical legislation.
Q4 What do you think of the following measures to support innovation, including for ‘unmet medical needs’?

<table>
<thead>
<tr>
<th>Measure</th>
<th>Very important</th>
<th>Important</th>
<th>Fairly important</th>
<th>Slightly important</th>
<th>Not important</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The current data and market protection periods for innovative medicines: 10 years of market protection, and 8 years of data protection.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Provide different data and market protection periods depending on the purpose of the medicine (i.e. longer period of protection in areas of unmet medical need).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Reduce the data and market protection periods to allow earlier access for generic and biosimilar medicines to the market.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Introduce new types of incentives(^\text{6}) on top of the existing data and market protection for medicines addressing an ‘unmet medical need’.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\[^{6}\] Examples of new incentives are a transferable exclusivity voucher or a priority review voucher. A transferable exclusivity voucher would give the legal right to extend the protection time period of any other patented medicinal product, in exchange for the successful regulatory approval of a specified medicine for unmet medical need (e.g. an antibiotic). The voucher would be transferable or saleable, and may impact the turnover and profitability levels of other products in a developer’s portfolio. A priority review voucher gives priority to the assessment of the application of the medicine in question or another medicine in the applicant’s portfolio.

| 5. Early scientific support and faster review/authorisation of a new promising medicine for an unmet medical need. |                |           |                  |                     |               |            |
| 6. Public listing of priority therapeutic areas of high unmet medical need to support product development by providing incentives. |                |           |                  |                     |               |            |
| 7. Require transparent reporting from companies about their research and development costs and public funding as a condition to obtain certain incentives. |                |           |                  |                     |               |            |
| 8. Other (please specify)                                                                 |                |           |                  |                     |               |            |
Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined measures, or would you like to justify/elaborate your replies?

800 character(s) maximum

- Different levels of incentives (and market exclusivity duration) should be foreseen depending on the UMN that the new medicine would cover, but the maximum of 8y and 10y should not extended. A list of priorities based on the EC evaluation published in August 2020 would be helpful to steer proven innovation where it is needed. To get incentives, transparent reporting of R&D costs should be mandatory, also considering that EU patients already pay the R&D costs through taxes.
- To increase access to medicines: (i) allow generics and biosimilars into the market once the period of protection is over and any attempt of hampering this should be financially punished; (ii) incentivise authorization of treatments developed in academic settings for non-commercial purposes (e.g., CAR-T).

ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) is the ability of microorganisms (such as bacteria, viruses, fungi or parasites) to survive and grow over time and no longer respond to medicines making infections harder to treat and increasing the risk of infections, severe illness and death. Antimicrobials include antibiotics, which are substances that fight bacterial infections. Overprescribing, overuse and inappropriate use of antibiotics are key drivers of AMR, leading to harmful health outcomes. The question below is intended to collect opinions on both the incentives for the development of new antimicrobials as well as possible option on their prudent use.

Q5 Should there be specific regulatory incentives for the development of new antimicrobials while taking into account the need for more prudent use and if so what should they be?

1000 character(s) maximum

N/A

FUTURE PROOFING: ADAPTED, AGILE AND PREDICTABLE REGULATORY FRAMEWORK FOR NOVEL PRODUCTS

Novel products and innovative solutions continue to challenge the understanding of a “medicinal product” with low volume, and cutting-edge products (e.g. medicines combined with self-learning artificial intelligence) becoming a new reality. ‘Bedside’ manufacture of more individualised medicines changes the way medicines are produced. There are classification and interplay challenges with other medical products, such as medical devices and substances of human origin, or related to the combination of clinical trials with in vitro diagnostics/medical devices and medicines. In addition, certain cell-based advanced therapy medicines are offered in hospital settings and are exempted from aspects of the pharmaceutical legislation. These developments offer possibilities for novel promising treatments and new ways of authorising and monitoring medicines but they are also testing the limits of the current regulatory system.
They need to be addressed to unfold their potential while safeguarding the principles of high quality, safety and efficacy of medicines.

Digital transformation is affecting the discovery, development, manufacture, evidence generation, assessment, supply and use of medicines. Medicines, medical technologies and digital health are becoming increasingly integral to overarching therapeutic options. These include systems based on artificial intelligence for prevention, diagnosis, better treatment, therapeutic monitoring and data for personalised medicines and other healthcare applications.

[8] Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer ground-breaking new opportunities for the treatment of disease and injury.
**Q6 How would you assess the following measures to create an adapted, agile and predictable regulatory framework for novel products?**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Very important</th>
<th>Important</th>
<th>Fairly important</th>
<th>Slightly important</th>
<th>Not important</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maintain the current rules.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Create a central mechanism in close coordination with other concerned authorities (e.g. those responsible for medical devices, substances of human origins) to provide non-binding scientific advice on whether a treatment/product should be classified as a medicine or not.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Make use of the possibility for 'regulatory sandboxes'(^9) in legislation to pilot certain categories of novel products/technologies.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[9] Some very innovative solutions fail to see the light of day because of regulations which might be outdated or poorly adapted for fast evolving technologies. One way to address this is through regulatory sandboxes. This enables innovative solutions not already foreseen in regulations or guidelines to be live-tested with supervisors and regulators, provided that the appropriate conditions are in place, for example to ensure equal treatment. Regulatory sandboxes provide up-to-date information to regulators and supervisors on, and experience with, new technology, while enabling policy experimentation. See COM(2020) 103 final.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Create adaptive regulatory frameworks (e.g. adapted requirements for authorisation and monitoring with possibility to adjust easily to scientific progress) for certain novel types of medicines or low volume products (hospital preparations) in coherence with other legal frameworks (e.g. medical devices and substances of human origin(^10)) and respecting the principles of quality, safety and efficacy.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[10] Substances that are donated by humans such as blood, plasma, cells, gametes, tissues and organs and are applied as therapy. Some substances of human origin can also become starting materials to manufacture medicines.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
5. Introduce an EU-wide centrally coordinated process for early dialogue and more coordination among clinical trial, marketing authorisation, health technology assessment bodies, pricing and reimbursement authorities and payers for integrated medicines development and post-authorisation monitoring.

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Other (please specify)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined measures, or would you like to justify/elaborate your replies?

800 character(s) maximum

- Patient representatives should contribute to the design of the clinical trials for MAA.
- RWE and RWD should be clearly regulated, also by learning from existing and past experiences. They can complement but surely not substitute clinical trials.
- A robust collection of high-quality data on the quality of life is increasingly important also because novel products are coming into the market with high uncertainty around their added value;
- Adaptive regulatory frameworks are needed to facilitate authorization of treatments developed in academic settings for non-commercial purposes.
- Usually the companies cannot provide convincing data on effectiveness and persistence.
- There is the need for payment models that take the underlying insecurity of the effectiveness into account.

Q7. Do you think that certain definitions and the scope of the legislation need to be updated to reflect scientific and technological developments in the sector (e.g. personalised medicines, bedside manufacturing, artificial intelligence) and if so what would you propose to change?

1000 character(s) maximum

Firstly, the pharmaceutical legislation needs to be aligned with the scientific developments but more importantly it needs to address the specificities of future health discoveries still in the R&D phase. Secondly, it is critical that the EC rewards and acknowledges the investments and the resources that charities, academia, and non-profit research centers dedicate for cancer research.

When it comes to definitions, the following should be added under art. 1:
- Orphan medicinal product
- health technology
- digital health
- ‘combined therapeutic products’

Under art 22, post-authorisation studies should be extended beyond safety reasons and include proven added value to the patient by collecting and analyzing RWD including patient-reported outcomes to generate RWE, which can establish added value of the drugs in a real world setting. The current legislation does not address adequately bedside manufacturing to guarantee its safety and quality.

REWARDS AND OBLIGATIONS RELATED TO IMPROVED ACCESS TO MEDICINES

Some medicines and therapies do not always reach patients in all EU countries, so patients in the EU still have different levels of access to medicines, depending on where they live. Even if a medicine received an EU-wide authorisation, companies are currently not obliged to market it in all EU countries. A company may decide not to market its medicines in, or decide to withdraw them from, one or more countries. This can be due to various factors, such as national pricing and reimbursement policies, size of the population and level of wealth, the organisation of health systems and national administrative procedures. Smaller markets in particular face challenges for availability and supplies of medicines.
Q8 How would you assess the following measures to improve patient access to medicines across the EU?

<table>
<thead>
<tr>
<th>Measure</th>
<th>Very important</th>
<th>Important</th>
<th>Fairly important</th>
<th>Slightly important</th>
<th>Not important</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maintain the current rules which provide no obligation to market medicines in all EU countries.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Require companies to notify their market launch intentions to regulators at the time of the authorisation of the medicine.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Introduce incentives for swift market launch across the EU.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Allow early introduction of generics in case of delayed market launch of medicines across the EU, while respecting intellectual property rights.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Require companies to place – within a certain period after authorisation – a medicine on the market of the majority of Member States, that includes small markets.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Require companies withdrawing a medicine from the market to offer another company to take over the medicine.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Introduce rules on electronic product information to replace the paper package leaflet.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Introduce harmonised rules for multi-country packages of medicines.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Other (please specify).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined measures, or would you like to justify/elaborate your replies?

800 character(s) maximum

- If companies notified the EMA on their market launch plans along with the explanation, this would clarify which MSs would be excluded. Then, to leave no country behind, companies should be asked to place the product on the remaining MSs within a certain period after the authorisation, timing variable depending on the dimension of the company. The joint procurement at EU level should be considered by the Commission when countries are excluded from the market launch.
- The policy option n. 3 is too open to interpretation. We propose to connect incentives and market exclusivity with the launch in most MS.
- Public production facility could be envisaged when a product is withdrawn from the market because not profitable but still essential to patients.

ENHANCE THE COMPETITIVE FUNCTIONING OF THE MARKET TO ENSURE AFFORDABLE MEDICINES

The affordability of medicines has implications for both public and household finances. It poses a growing challenge to pay for medicines in the majority of Member States. Often, innovative medicines have higher prices, while there are growing concerns among stakeholders about the real-life effectiveness of some medicines and related overall costs. This puts the budgetary sustainability of health systems at risk, and reduces the possibilities for patients to have access to these medicines. Generics and biosimilars\(^{11}\) of medicines which no longer benefit from intellectual property protection (off-patent medicines) may provide accessible and affordable treatments. They also increase the availability of alternative treatment options for patients. They may also increase competition between available medicines. However, experience shows that there are still barriers for medicines entering the EU market, including for generics or biosimilars.

\(^{11}\) “Generics” are copies of medicines based on simple or chemical molecules; “biosimilars” are copies of medicines based on biological molecules.

Q9 In your view, to what extent would the following measures support access to affordable medicines?

<table>
<thead>
<tr>
<th>Measure</th>
<th>To a great extent</th>
<th>To a certain extent</th>
<th>No change</th>
<th>Very little</th>
<th>Not at all</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maintain the current rules.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[19]
2. Stimulate earlier market entry through a broader possibility to authorise generics/biosimilars despite ongoing patent protection ('Bolar exemption').

[12] The Bolar exemption allows companies to conduct research on patent protected medicines under the condition that it is with a view to apply for a marketing authorisation for a generic.

3. Create a specific (regulatory) incentive for a limited number of biosimilars that come to the market first.

4. Introduce an EU-wide scientific recommendation on interchangeability for specific biosimilars.

5. Introduce other, non-legislative measures, such as joint procurement to reinforce competition while addressing security of supply and environmental challenges.

6. Other (please specify).

Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined measures, or would you like to justify/elaborate your replies?

800 character(s) maximum

- Joint procurement to help MSs to access affordable health technologies by (i) removing obstacles that prevent patients from accessing affordable medicines for non-communicable diseases, (ii) coordinating with the EMA and the EUnetHTA joint assessments of new health technologies to make the HTA streamlined and efficient.
- The EU could encourage MSs to join resources to conduct joint horizon scanning.
- Encourage the entry of generics and biosimilars.
- Measure the extent of public investment in R&D and ensure taxpayers do not pay twice or more.
- Invest in public research covering UMNs with conditionalities linked to affordability and access.
- Steer a fair level playing field between governments and pharma companies in pricing negotiations.
- Policy option n. 3 is not clear.

**REPURPOSING OF MEDICINES**

Repurposing is the process of identifying a new use for an established medicine in a disease or condition other than that it is currently authorised for. Repurposing of older (off-patent) medicines constitutes an emerging and dynamic field of medicines development, often led by academic units and medical research charities, with the potential for faster development times and reduced costs as well as lower risks for companies. This is because repurposing commonly starts with substances that have already been tested.
and many have demonstrated an acceptable level of safety and tolerability. The objective is to identify the opportunities and address any regulatory burdens to facilitate repurposing of off-patent, affordable medicines.

Q10 What measures could stimulate the repurposing of off-patent medicines and provide additional uses of the medicine against new diseases and medical conditions? Please justify your answers.

1000 character(s) maximum

- As reported in the recently published policy brief titled ‘Repurposing of medicines in oncology’, several potential solutions have been identified to facilitate non-commercial repurposing. They include (i) improving the selection of candidates, (ii) facilitating generation of clinical evidence, (iii) streamlining regulated processes, (iv) improving coordination between stakeholders and ensuring adequate funding. Public–private partnerships involving research, registration and manufacturing (guaranteed volumes for non-profitable compounds) of repurposed medicines for cancer could also be explored.
- EMA should have the capacity to evaluate clinical evidence for a new indication of researchers and non-profit organisations. (assessing off-label use in a clinical study, with the intention of moving to on-label use).
- Non-profit organisations should be equipped with simple, harmonised procedures. They also need support and scientific advice about how to handle these procedures.

SECURITY OF SUPPLY OF MEDICINES

Shortages of medicines and the vulnerabilities in the pharmaceutical supply chain continue to be concerns in the EU. Shortages of medicines can have serious impacts on patient care. Under the current pharmaceutical legislation, pharmaceutical companies and wholesalers must, within the limits of their responsibilities, ensure a continued supply of medicines once they are placed on the market in the EU. Companies must also notify national authorities at least two months before an expected shortage or planned market withdrawal.
### Q11 What is your view on the following measures to ensure security of supply of medicines in the EU?

<table>
<thead>
<tr>
<th>Measure</th>
<th>Very important</th>
<th>Important</th>
<th>Fairly important</th>
<th>Slightly important</th>
<th>Not important</th>
<th>Don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maintain the current rules.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Earlier reporting of shortages and market withdrawals to national authorities in a common format.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Companies to have shortage prevention plans.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Companies to have safety stocks.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Monitoring of supply and demand at national level.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Introduce a shortage monitoring system at EU level.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Require companies to diversify their supply chains, in particular the number of key suppliers of medicines and components.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Companies to provide more information to regulators on their supply chain.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Introduce penalties for non-compliance by companies with proposed new obligations.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. EU coordination to help identify areas where consolidation in the supply chain has reduced the number of suppliers.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Other (please specify)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined measures, or would you like to justify/elaborate your replies?

800 character(s) maximum

- Legal obligations on MAHs to develop shortage mitigation AND prevention plans should be in place. The first objective should be preventing shortages and address possible causes before the disruption occurs. Mitigation plans should be accompanied by prevention plans and these should be public, compulsory, and with sanctions attached if not fulfilled. Lessons can be learnt from the management of covid-19 vaccines across the EU.
- Safety stocks managed in a rotational way depending on the date of expiration would be critical to ensure that medicines are available also in case of crisis.
- The diversification of supplier would be beneficial for companies and patients. Avoid monopolies and guarantee medicine provision also in case of supply disruption should be the goal.

QUALITY AND MANUFACTURING

Medicines manufactured for the EU market must comply with the principles and guidelines of good manufacturing practice (GMP). GMP describes the minimum standard that a medicines manufacturer must meet in their production processes. GMP requires that medicines are of consistent high quality, are appropriate for their intended use and meet the requirements of the marketing authorisation or clinical trial authorisation.

Q12 What is your opinion of the following measures to ensure manufacturing and distribution of high quality products?

<table>
<thead>
<tr>
<th></th>
<th>Very adequate</th>
<th>Adequate</th>
<th>Neutral</th>
<th>Less adequate</th>
<th>Not adequate</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maintain the current rules.</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>2. Strengthen manufacturing and oversight rules.</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>3. Adapt manufacturing rules to reflect new manufacturing methods.</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
</tbody>
</table>
4. Include selected environmental requirements for manufacturing of medicines in line with the one health approach on antimicrobial resistance\textsuperscript{13}.

[13] The one-health approach is a holistic and multi-sectorial approach to addressing antimicrobial resistance since antimicrobials used to treat infectious diseases in animals may be the same or be similar to those used in humans.

5. Increase Member State cooperation and surveillance of the supply chain in the EU and third countries.

6. Strengthen and clarify responsibilities of business operators over the entire supply chain on sharing information on quality, safety and efficacy.

7. Other (please specify).

Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined measures, or would you like to justify/elaborate your replies?

800 character(s) maximum

- It is essential to have a clear overview of all the steps of the pharmaceutical pathway, from raw ingredients coming from outside the EU to final packaging. Indeed, if only step is missing, the product does not reach the patient.
- It is important to increase transparency of the supply in EU to avoid unfair competition among MSs and encourage collaboration.
- It is essential to maintain an open strategic autonomy to avoid protectionist measures, even beyond healthcare.
- An increased local production of pharmaceuticals should be carefully assessed considering the impact on the economy, environment, health, labor market.
- It is critical to clarify accountability and responsibility of the actors involved and to enforce adequate measures should supply duties not be fulfilled.

ENVIRONMENTAL CHALLENGES

While access to pharmaceuticals is a priority, it is also important that the environmental impacts of those pharmaceuticals are as low as possible. The environmental risk assessments (ERAs) is currently not taken
into account in the overall benefit/risk analysis which influences the delivery of a marketing authorisation (MA) of a medicine. ERA can influence risk management measures. Yet, ERA results are not decisive in the MA process.
Q13 How would you assess the following measures to ensure that the environmental challenges emerging from human medicines are addressed?

<table>
<thead>
<tr>
<th>Measure</th>
<th>Very important</th>
<th>Important</th>
<th>Fairly important</th>
<th>Slightly important</th>
<th>Not important</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maintain the current rules.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Strengthen the environmental risk assessment during authorisation of a medicine, including risk mitigation measures, where appropriate.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Harmonize environmental risk assessment by national regulators, including risk mitigation measures.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Increase information to the health care professionals and the general public about the assessment of environmental risks of medicines.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Allow companies to use existing data about environmental risks for authorisations of a new medicine to avoid duplicating tests.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Other (please specify).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Is there any other aspect you would like to mention, for example on the potential economic, social, environmental or other impacts of the outlined measures, or would you like to justify/elaborate your replies?

800 character(s) maximum

The impact of pharmaceuticals on the environment is critical because human beings, animals, and environment are interconnected and a ‘one-health approach’ is needed in all policies. Nevertheless, it is also important to support pharmaceutical companies with limited resources to renovate their buildings and machineries to reduce pollution. It is fair to set requirements but it is also important to place stakeholders in the position to change. It is of outmost relevance to analyse the economic, social, economic consequences should the number of pharmaceutical production sites increase in the next years. Ethical considerations play an important role in this conversation.

Q14 Is there anything else you would like to add that has not been covered in this consultation?

900 character(s) maximum

- Data and market protection should be linked to conditions, such as placing on the market of a pharmaceutical product on most/all MS, at a fair price.
- Compulsory license is an important tool to protect the balance between the interests of the owner of the IP on the one hand and society on the other. During the 8y period of data exclusivity, a compulsory license cannot function, because a firm that wants to make use of the compulsory license needs access to the data. Therefore, an exception must be incorporated in European data-exclusivity law to enable the granting of compulsory licences.
- Develop alternative ways to (i) incentivise and award medicine development (eg delinkage) and (ii) ensure R&D models result in affordable products.

Q15 In case you would like to share a document that substantiates your replies, please upload it below (optional).

Only files of the type pdf,txt,doc,docx,odt,rtf are allowed

f5a09ccc-65e4-454e-9ed6-12f2725c96f1/ECL_Attachment_pharmaceutical_legislation_consultation_final.pdf

Contact
EU-PHARMACEUTICAL-STRATEGY@EC.EUROPA.EU